格洛菲他马布后复发的预后很差,CD20损失率很高
Samuel Grigg1,2, Adrian Minson1,2, Elizabeth Prins2
1Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
British journal of haematology
|May 9, 2024
概括
在glofitamab后复发的侵略性B细胞非霍奇金淋巴瘤的预后不好. 较高的CD20损失率表明对CD20xCD3双特异抗体的耐药性,需要新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 免疫治疗是一种免疫疗法.
背景情况:
- 侵袭性B细胞非霍奇金淋巴瘤 (NHL) 是一个重大的临床挑战.
- 格洛菲他马布是一种CD20xCD3双特异性抗体,为复发/耐药NHL提供了一种新的治疗方式.
- 了解耐药机制对于优化治疗结果至关重要.
研究的目的:
- 为了评估在glofitamab治疗后进展的具有攻击性B细胞NHL的患者的结果.
- 调查CD20损失在这个患者队列中的发生率和影响.
- 为了确定对CD20xCD3双特异抗体的潜在耐药性机制.
主要方法:
- 对具有侵略性B细胞NHL的患者的回顾性审查.
- 在glofitamab治疗后对治疗反应和生存数据的分析.
- 在复发时评估CD20表达水平.
主要成果:
- 在glofitamab后复发的患者中观察到不良预后,救援疗法反应率低.
- 平均整体存活时间是4.1个月后的进展.
- 在复发时检测到CD20损失的高率 (59%),这表明了抵抗机制.
结论:
- CD20损失是导致对CD20xCD3双特异抗体 (如glofitamab) 耐药性的重要因素.
- 对CD20损失机制的进一步研究是有必要的.
- 需要开发新的非CD20向疗法,以治疗CD20向治疗后复发的患者.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.3K
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
493
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
